SEC Form 3 · accession 0000899243-19-001649

CytoDyn Inc. · CYDY

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Jan 10, 2019

Accepted (ET)

Jan 22, 2019 · 5:54 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001175680

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F2	holding	—	—		—	963,333	I	See Footnote
Common Stock^F3	holding	—	—		—	1,675,280	I	See Footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Warrant (Right to Buy)^F2,F1	$0.75	holding	—	—	—	—	Jan 28, 2021	Common Stock	166,666	—	I
Warrant (Right to Buy)^F2,F1	$0.75	holding	—	—	—	—	Feb 16, 2023	Common Stock	600,000	—	I
Warrant (Right to Buy)^F2,F1	$0.30	holding	—	—	—	—	Dec 28, 2023	Common Stock	1,000,000	—	I
Warrant (Right to Buy)^F3,F1	$0.75	holding	—	—	—	—	Sep 8, 2022	Common Stock	384,615	—	I
Warrant (Right to Buy)^F3,F1	$0.75	holding	—	—	—	—	Sep 14, 2023	Common Stock	500,000	—	I
Convertible Promissory Note^F2,F5,F1,F4	$0.50	holding	—	—	—	—	Sep 28, 2019	Common Stock	2,000,000	—	I

F1The securities were exercisable on the date of the event which required the filing of this report.
F2The reported securities of CytoDyn Inc. (the "Company") are held by LRFA, LLC, a Delaware limited liability company ("LRFA"). David F. Welch, Ph.D. is the sole managing member of LRFA. Dr. Welch disclaims beneficial ownership of the securities held by LRFA, except to the extent of his pecuniary interest therein.
F3The reported securities of the Company are held by David Welch Tr Ua 03/02/2000 Welch Charitable Remainder Unitrust Agreement II, for which Dr. Welch is a trustee.
F4Does not include additional shares issuable upon conversion of accrued interest.
F5Subject to adjustment in the event of certain stock split or reverse stock split recapitalizations.